176961-50-5

Basic information

• Product Name: 2-(4-BROMO-PHENYL)-OXAZOLE
• Synonyms: 2-(4-bromophenyl)-1,3-oxazole;Oxazole, 2-(4-broMophenyl)-;2-(4-BROMO-PHENYL)-OXAZOLE
• CAS NO: 176961-50-5
• Molecular Formula: C₉H₆BrNO
• Molecular Weight: 224.05
• Mol File: 176961-50-5.mol

Chemical Properties

• Boiling Point: 296.613 °C at 760 mmHg
• Flash Point: 133.187 °C
• Appearance: /
• Density: 1.525 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(4-BROMO-PHENYL)-OXAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMO-PHENYL)-OXAZOLE(176961-50-5)
• EPA Substance Registry System: 2-(4-BROMO-PHENYL)-OXAZOLE(176961-50-5)

Safety Data

• Hazardous Substances Data: 176961-50-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-BROMO-PHENYL)-OXAZOLE is used as a building block for the synthesis of various biologically active compounds, such as drugs and pharmaceutical agents. Its unique structure allows for the development of new molecules with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, 2-(4-BROMO-PHENYL)-OXAZOLE serves as a key intermediate in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds.
Used in Organic Synthesis:
2-(4-BROMO-PHENYL)-OXAZOLE is used as a reagent in organic synthesis for the formation of new carbon-carbon bonds. Its presence in the reaction can facilitate the formation of complex molecular structures, contributing to the development of novel organic compounds.
Used in Medicinal Chemistry Research:
Due to its potential antimicrobial and anti-inflammatory properties, 2-(4-BROMO-PHENYL)-OXAZOLE is a valuable research tool in medicinal chemistry studies. It can be used to explore new avenues for drug discovery and development, particularly in the areas of infectious diseases and inflammatory conditions.

Upstream product

• 13518-80-4 2-trimethylsilyl-2H-1,2,3-triazole 
• 586-75-4 4-chlorobenzoyl chloride 
• 22483-09-6 2,2-dimethoxyethylamine 
• 623-00-7 4-bromobenzenecarbonitrile 
• 189120-01-2 2-(4-bromo-phenyl)-4,5-dihydro-oxazole 
• 872-36-6 vinylene carbonate 
• 698-67-9 p-bromobenzamide 
• 288-36-8 1,2,3-triazole 

Downstream Products

• 845616-98-0 tert-butyl 4-(4-(oxazol-2-yl)phenyl)piperazine-1-carboxylate 
• 220697-59-6 2-(4-(piperazin-1-yl)phenyl)oxazole 
• 1428536-39-3 2-(4-(4-(thiophen-2-ylmethyl)piperazin-1-yl)phenyl)oxazole 
• 1428536-38-2 2-(4-(4-((5-methylfuran-2-yl)methyl)piperazin-1-yl)phenyl)oxazole 
• 1428536-37-1 2-(4-(4-(pyridin-3-ylmethyl)piperazin-1-yl)phenyl)oxazole 
• 1402636-54-7 (2R)-2-methyl-2-(methylsulfonyl)-4-{4-[4-(1,3-oxazol-2-yl)phenyl]-1H-pyrazol-1-yl}butanoic acid 
• 1402636-55-8 (2R)-2-methyl-2-(methylsulfonyl)-4-{4-[4-(1,3-oxazol-2-yl)phenyl]-1H-pyrazol-1-yl}-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1402636-53-6 (2R)-N-hydroxy-2-methyl-2-(methylsulfonyl)-4-{4-[4-(1,3-oxazol-2-yl)phenyl]-1Hpyrazol-1-yl}butanamide 
• 501944-79-2 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,3-oxazole 
• 176960-47-7 N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide 
• 176961-14-1 N-(3,4-dimethyl-5-isoxazolyl)-N-[(methoxyethoxy)methyl]-4'-(2-oxazolyl)[1,1'-biphenyl]-2-sulfonamide 

Relevant articles and documents

DDQ-induced dehydrogenation of heterocycles for c-c double bond formation: Synthesis of 2-thiazoles and 2-oxazoles

Strong as an Ox: 2-Thiazoles and 2-oxazoles are formed by oxidation of 2-thiazolines and 2-oxazolines without requiring substituents at the C4 and C5 positions. DDQ plays an important role as the oxidant in this transformation and metal is unnecessary. This general procedure shows good functional group tolerance and provides a wide variety of 2-thiazoles and 2-oxazoles in moderate to excellent yields.

SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel piperidine ether derivatives having affinity for the histamine H3 receptor, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

NOVEL COMPOUNDS

The present invention relates to novel diazepanyl derivatives of formula (I) having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

Azabicyclic heterocycles as cannabinoid receptor modulators

The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.

Preparation of 2-substituted oxazoles

A simple and economical method for 2-substituted oxazole synthesis and its scope are described.

Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonists

The synthesis and structure-activity relationship (SAR) studies of a series of 4'-oxazolyl-N-(3,4-dimethyl-5-isoxazolyl)[1, 1'-biphenyl]-2-sulfonamide derivatives as endothelin-A (ET(A)) receptor antagonists are described. The data reveal a remarkable improvement in potency and metabolic stability when the 4'-position of the biphenylsulfonamide is substituted with an oxazole ring. Additional 2'-substitution of an acylaminomethyl group further increased the binding activity and provided one of the first subnanomolar ET(A)-selective antagonists in the biphenylsulfonamide series (17, ET(A) K(i) = 0.2 nM). Among the compounds described, 3 (N-(3,4-dimethyl-5-isoxazolyl)-4'-(2-oxazolyl)[1,1'-biphenyl]-2-s ulfonamide; BMS-193884) had the optimum pharmacological profile and was therefore selected as a clinical candidate for studies in congestive heart failure.